Maura Campitelli

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Hidden patterns, different outcomes: un-supervised machine-learning clustering in oligometastatic gynecologic cancer.

Hidden patterns, different outcomes: un-supervised machine-learning clustering in oligometastatic gynecologic cancer.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: February 11, 2026

Pelvic insufficiency fractures in cervical cancer patients treated with definitive chemoradiation: impact of dosimetric and clinical factors.

Pelvic insufficiency fractures in cervical cancer patients treated with definitive chemoradiation: impact of dosimetric and clinical factors.

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: November 02, 2025

Reassessing the risks: toxicity of stereotactic ablative radiotherapy after bevacizumab in oligometastatic ovarian cancer-a new perspective for radiation oncologists?

Reassessing the risks: toxicity of stereotactic ablative radiotherapy after bevacizumab in oligometastatic ovarian cancer-a new perspective for radiation oncologists?

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 18, 2025

MRI-guided stereotactic radiotherapy for oligometastatic peritoneal carcinomatosis: toward integrative oncologic approaches.

MRI-guided stereotactic radiotherapy for oligometastatic peritoneal carcinomatosis: toward integrative oncologic approaches.

Journal: Clinical & experimental metastasis

Published: March 12, 2025

Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3/RAD).

Treatment of Oligometastatic Parenchymal Lesions in Ovarian Cancer With Stereotactic Ablative Radiation Therapy: A Multicenter Prospective Phase 2 Trial (MITO RT3/RAD).

Journal: International journal of radiation oncology, biology, physics

Published: January 14, 2025

Stereotactic body radiotherapy and poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a knowledge and attitudes survey in collaboration with the Italian Association of Radiation Oncology (AIRO) and Multicenter Italian Trials in Ovarian Cancer (MITO) groups.

Stereotactic body radiotherapy and poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a knowledge and attitudes survey in collaboration with the Italian Association of Radiation Oncology (AIRO) and Multicenter Italian Trials in Ovarian Cancer (MITO) groups.

Journal: Anti-cancer drugs

Published: January 09, 2025

Which is the best timing to assess response after chemoradiation in locally advanced cervical cancer (BRILACC)?

Which is the best timing to assess response after chemoradiation in locally advanced cervical cancer (BRILACC)?

Journal: Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]

Published: December 27, 2024

Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence.

Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence.

Journal: ESMO open

Published: August 30, 2024

Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial.

Stereotactic Ablative Radiation Therapy for Oligometastatic Ovarian Cancer Lymph Node Disease: The MITO-RT3/RAD Phase II Trial.

Journal: International journal of radiation oncology, biology, physics

Published: July 05, 2024

Correlation between radiation dose to bone marrow subregions and acute hematologic toxicity inendometrial cancer treated with external beam radiotherapy.

Correlation between radiation dose to bone marrow subregions and acute hematologic toxicity inendometrial cancer treated with external beam radiotherapy.

Journal: Clinical and translational radiation oncology

Published: June 29, 2024

Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study.

Stereotactic Body Radiation Therapy for Oligoprogressive Ovarian Cancer Patients Treated During Poly(ADP-Ribose)-Polymerase Inhibitor Maintenance: Efficacy and Adverse Events From the Epimetheo Retrospective Study.

Journal: International journal of radiation oncology, biology, physics

Published: May 11, 2024

Prevention and management of radiotherapy-related toxicities in gynecological malignancies. Position paper on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology).

Prevention and management of radiotherapy-related toxicities in gynecological malignancies. Position paper on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology).

Journal: La Radiologia medica

Published: March 07, 2024

Showing 1-12 of 36

Last Updated: 09/26/2026